Tandem Diabetes Care Announces Upcoming Conference Presentations

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced its participation in several upcoming investor conferences.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

02/15/2023 - 04:05 PM EST

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences:

Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Thursday, March 2, 2023 at 2:45pm ET (11:45am PT),
Cowen 43^rd Annual Health Care Conference on Monday, March 6, 2023 at 12:50pm ET (9:50am PT),
Raymond James & Associates’ 44^th Annual Institutional Investors Conference on Wednesday, March 8, 2023 at 9:50am ET (6:50am PT),
Oppenheimer 33^rd Annual Healthcare Conference on Monday, March 13, 2023 at 8:40am ET (5:40am PT), and
Barclays Global Healthcare Conference on Tuesday, March 14, 2023 at 11:15am ET (8:15am PT).

The Company update presentation will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care and Control-IQ are trademarks registered in the U.S. and/or other countries and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.